VIEWRAY INC (VRAY) Stock Price, Forecast & Analysis
USA - NASDAQ:VRAY - US92672L1070 - Common Stock
VRAY Key Statistics, Chart & Performance
The current stock price of VRAY is 0.025 USD. In the past month the price decreased by -93.75%. In the past year, price decreased by -99.18%.
VRAY Latest News, Press Relases and Analysis
VRAY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.17 | 227.29B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.82 | 196.99B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.81 | 152.16B | ||
| SYK | STRYKER CORP | 27.5 | 138.48B | ||
| BDX | BECTON DICKINSON AND CO | 13.39 | 55.33B | ||
| IDXX | IDEXX LABORATORIES INC | 54.71 | 55.19B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.58 | 50.67B | ||
| RMD | RESMED INC | 24.69 | 35.68B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.94 | 33.40B | ||
| PODD | INSULET CORP | 72.8 | 23.42B | ||
| DXCM | DEXCOM INC | 31.22 | 22.77B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.11 | 17.81B |
Related stock screener links
About VRAY
Company Profile
ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. The company is headquartered in Oakwood Village, Ohio and currently employs 295 full-time employees. The company went IPO on 2014-11-04. The MRIdian MR-Guided Radiation Therapy System integrates diagnostic MR imaging with radiation therapy delivery to enable on-table adaptive treatments with real-time tissue tracking and automatic beam gating. The MRIdian is comprised of three components, namely magnetic resonance imaging (MRI) system, radiation delivery system, and integrated treatment planning and delivery software. MRIdian employs MRI-based technology to provide real-time imaging that targets tumors from the surrounding soft tissue and other critical organs, both before and during radiation treatment delivery. MRIdian offers MR-guided imaging that provides tissue visualization compared to cone-beam computed tomography (CBCT), to enable contouring and reduced margins. The firm has installed approximately 56 MRIdian systems at hospitals, which are used to treat a variety of solid tumors.
Company Info
VIEWRAY INC
2 Thermo Fisher Way
Oakwood Village OHIO 44146 US
CEO: Scott Drake
Employees: 295
Phone: 14407033210.0
VIEWRAY INC / VRAY FAQ
What does VRAY do?
ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. The company is headquartered in Oakwood Village, Ohio and currently employs 295 full-time employees. The company went IPO on 2014-11-04. The MRIdian MR-Guided Radiation Therapy System integrates diagnostic MR imaging with radiation therapy delivery to enable on-table adaptive treatments with real-time tissue tracking and automatic beam gating. The MRIdian is comprised of three components, namely magnetic resonance imaging (MRI) system, radiation delivery system, and integrated treatment planning and delivery software. MRIdian employs MRI-based technology to provide real-time imaging that targets tumors from the surrounding soft tissue and other critical organs, both before and during radiation treatment delivery. MRIdian offers MR-guided imaging that provides tissue visualization compared to cone-beam computed tomography (CBCT), to enable contouring and reduced margins. The firm has installed approximately 56 MRIdian systems at hospitals, which are used to treat a variety of solid tumors.
What is the stock price of VIEWRAY INC today?
The current stock price of VRAY is 0.025 USD. The price decreased by -39.9% in the last trading session.
Does VIEWRAY INC pay dividends?
VRAY does not pay a dividend.
What is the ChartMill technical and fundamental rating of VRAY stock?
VRAY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for VIEWRAY INC?
VIEWRAY INC (VRAY) has a market capitalization of 4.58M USD. This makes VRAY a Nano Cap stock.
What is the next earnings date for VRAY stock?
VIEWRAY INC (VRAY) will report earnings on 2023-10-30, after the market close.
VRAY Technical Analysis
VRAY Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VRAY. While VRAY seems to be doing ok healthwise, there are quite some concerns on its profitability.
VRAY Financial Highlights
Over the last trailing twelve months VRAY reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS increased by 6.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
VRAY Forecast & Estimates
12 analysts have analysed VRAY and the average price target is 1.22 USD. This implies a price increase of 4796% is expected in the next year compared to the current price of 0.025.
For the next year, analysts expect an EPS growth of 12.95% and a revenue growth -9.41% for VRAY